Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr

Aurobindo Pharma Board Meeting Date

Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.

Aurobindo Pharma Other Announcement

Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.

Aurobindo Pharma Business Update

Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.

Aurobindo Pharma Acquisition

Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.

Aurobindo Pharma Acquisition Worth ₹146.4 Cr

Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.

Value

₹146.4 Cr

Aurobindo Pharma Product Launch

Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.

Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr

Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.

Value

₹2.75 Cr

Execution

Completion expected by 26 January 2027

TVS Holdings Merger & Restructuring

TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Fortis Healthcare Merger & Restructuring Worth ₹277 Cr

Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.

Value

₹277.0 Cr

Vraj Iron & Steel Merger & Restructuring Worth ₹4.55 Cr

Vraj Iron and Steel transferred 396,000 MVK Industries shares to promoter Gopal Sponge for Rs 4.55 Crore. The sale was completed on October 28, 2026.

Value

₹4.55 Cr

KPIT Technologies Merger & Restructuring Worth ₹19.2 Cr

KPIT Technologies will incorporate a new Vietnam subsidiary for mobility engineering, with 100% control. The company commits USD 2 million (about Rs 19.20 Crore) in cash.

Value

₹19.20 Cr